Sanofi-Aventis (France) Hopes to Win Genzyme Corporation for $76/Share; Said to be Ceiling Price

January 14, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

(Reuters) - French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (NasdaqGS:GENZ - News) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe

Sanofi